ASCO 2016

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

By

Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.

Analysis Reveals Potentially Targetable Fusion Genes in Various Cancer Types

Analysis Reveals Potentially Targetable Fusion Genes in Various Cancer Types

By

An RNA assay for common gene fusions is now validated and available to guide patients with cancer to clinical trials and through drug treatment options.

Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer

Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer

By

Serum levels of carbonic anhydrase IV (sCAIX) were associated with improved pathologic complete response rates.

Clinical Benefit for Patients When Treated Based on ctDNA Findings

Clinical Benefit for Patients When Treated Based on ctDNA Findings

By

Nearly half of patients with advanced cancer treated with FDA-approved therapies had alterations in circulating tumor DNA (ctDNA).

Single-cell RNA-sequencing Can Resolve Malignant, Non-malignant Heterogeneity

Single-cell RNA-sequencing Can Resolve Malignant, Non-malignant Heterogeneity

By

Single-cell RNA-sequencing can resolve the heterogeneity of both malignant and non-malignant tumor components.

Biosimilar to Trastuzumab Comparable in Efficacy, Safety for Advanced HER2+ Breast Cancer

Biosimilar to Trastuzumab Comparable in Efficacy, Safety for Advanced HER2+ Breast Cancer

By

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

Funding, Informatics System, Clinical Data Capture Among Barriers to Effective Data Sharing

Funding, Informatics System, Clinical Data Capture Among Barriers to Effective Data Sharing

By

Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.

Neoadjuvant TCH + Pertuzumab Linked to Better pCR vs T-DM1 + Pertuzumab in Early Breast Cancer

Neoadjuvant TCH + Pertuzumab Linked to Better pCR vs T-DM1 + Pertuzumab in Early Breast Cancer

By

Neoadjuvant docetaxel plus carboplatin and trastuzumab followed by pertuzumab (TCH+P) was associated with improved pathologic complete response rate .

Study Evaluates Adding, Substituting Neoadjuvant Lapatinib for HER2+ Breast Cancer

Study Evaluates Adding, Substituting Neoadjuvant Lapatinib for HER2+ Breast Cancer

By

Adding lapatinib to trastuzumab plus weekly paclitaxel after an anthracycline was not beneficial.

Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast Cancer

Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast Cancer

By

Replacing paclitaxel with nab-paclitaxel in an anthracycline regimen failed to significantly improve the pathologic complete response rate.

Intermittent Docetaxel Non-inferior in 1-year Survival for Patients With CRPC

Intermittent Docetaxel Non-inferior in 1-year Survival for Patients With CRPC

By

Intermittent docetaxel could be an option for patients with CRPC.

Weekly Paclitaxel, Bevacizumab Should Be Considered for Second- or Third-line Treatment of NSCLC

Weekly Paclitaxel, Bevacizumab Should Be Considered for Second- or Third-line Treatment of NSCLC

By

Weekly paclitaxel plus bevacizumab significantly improved progression-free survival and objective response rate in NSCLC.

Web Application Improves Survival in Advanced Lung Cancer

Web Application Improves Survival in Advanced Lung Cancer

By

A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.

Adding Enzalutamide to Abiraterone + Leuprolide Not Effective for Localized High-risk PCa

Adding Enzalutamide to Abiraterone + Leuprolide Not Effective for Localized High-risk PCa

By

Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.

Shorter RT Fractionation Schedule Feasible for Localized Prostate Cancer

Shorter RT Fractionation Schedule Feasible for Localized Prostate Cancer

By

A hypofractionated radiotherapy regimen administered in 20 fractions over 4 weeks was noninferior in patients with localized prostate cancer.

Adjuvant Docetaxel Fails to Improve Biochemical DFS in High-risk Prostate Cancer

Adjuvant Docetaxel Fails to Improve Biochemical DFS in High-risk Prostate Cancer

By

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

TRUS-biopsy Poorly Detects Prostate Cancer

TRUS-biopsy Poorly Detects Prostate Cancer

By

Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

By

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

Extending Hormone Therapy to 10 Years May Reduce Breast Cancer Recurrence Without Negatively Affecting QoL

Extending Hormone Therapy to 10 Years May Reduce Breast Cancer Recurrence Without Negatively Affecting QoL

By

Extending aromatase inhibitor therapy for 5 years beyond an initial 5 years resulted in a 34% reduction in recurrence in early-stage breast cancer.

Cobimetinib Plus Atezolizumab Active in Colorectal Cancer

Cobimetinib Plus Atezolizumab Active in Colorectal Cancer

By

Cbimetinib and atezolizumab was well tolerated and demonstrated encouraging clinical activity in microsatellite stable colorectal cancer (CRC).

Nivolumab ± Ipilimumab Demonstrates Encouraging Activity, Survival in mCRC

Nivolumab ± Ipilimumab Demonstrates Encouraging Activity, Survival in mCRC

By

Nivolumab with or without ipilimumab was well tolerated in most patients with high microsatellite instability metastatic colorectal cancer (mCRC).

High Immunoscore Associated With Prolonged Time to Recurrence in Colon Cancer

High Immunoscore Associated With Prolonged Time to Recurrence in Colon Cancer

By

In patients with stage I, II, or III colon cancer, high Immunoscore was associated with significantly longer time to recurrence.

More 'Real-world' Data Needed on Cost of Cancer Treatments

More 'Real-world' Data Needed on Cost of Cancer Treatments

By

More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers.

Drug, Genomic Innovations Have Transformed Thyroid Cancer Treatment

Drug, Genomic Innovations Have Transformed Thyroid Cancer Treatment

By

There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.

Low Peripheral TCR Clonality Linked to Improved Survival With Atezolizumab

Low Peripheral TCR Clonality Linked to Improved Survival With Atezolizumab

By

In patients with metastatic urothelial carcinoma treated with atezolizumab, low peripheral T-cell receptor (TCR) clonality was associated with survival.

WNT/beta-catenin  Pathway Signaling Activated in Most Solid Tumors

WNT/beta-catenin Pathway Signaling Activated in Most Solid Tumors

WNT/β-catenin pathway signaling is associated with T cell exclusion and is activated in most human solid tumors, including colon, kidney, and lung tumors.

Treating Anti-PD-1-treated Patients With mNSCLC Beyond Progression Generally Not Effective

Treating Anti-PD-1-treated Patients With mNSCLC Beyond Progression Generally Not Effective

By

Patients with non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (anti-PD-1) therapy generally do not benefit from treatment.

Frontline Nivolumab Plus Ipilimumab Demonstrates Clinical Activity in Advanced NSCLC

Frontline Nivolumab Plus Ipilimumab Demonstrates Clinical Activity in Advanced NSCLC

By

First-line therapy with nivolumab in combination with ipilimumab demonstrated clinical activity in non-small cell lung cancer (NSCLC).

Older Pts With NSCLC Receiving CRT Had Worse OS, Similar PFS vs Younger Pts

Older Pts With NSCLC Receiving CRT Had Worse OS, Similar PFS vs Younger Pts

By

Older patients receiving concurrent chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) had worse overall survival.

Geriatric Assessment May Improve Selection of Older Patients for Concurrent CRT

Geriatric Assessment May Improve Selection of Older Patients for Concurrent CRT

By

Geriatric assessmentmay improve the selection of older patients with stage III non-small cell lung cancer (NSCLC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs